© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
January 20, 2023
The panel closes their discussion by musing on the future of HER2 mBC treatments.
January 06, 2023
A discussion on the prevalence and treatment difficulties of leptomeningeal metastases in HER2+ mBC.
The panel discusses the systemic therapy options for patients with HER2+ mBC with brain metastases before moving to whole brain radiation therapy.
Andrew Brenner, MD, presents the case of a 62-year-old patient with stage II HER2+ mBC presenting with both pulmonary and brain metastases.
Joyce O’Shaughnessy, MD, starts a conversation on managing the adverse events of tucatinib therapy in patients with HER2+ mBC with brain metastases.
December 22, 2022
The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.
Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.
December 15, 2022
Heather McArthur, MD, describes what treatment options she would consider in the third-line setting for HER2+ mBC.
Andrew Brenner, MD, explains when physicians should screen patients with HER2+ breast cancer for brain metastases.
December 08, 2022
Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.